These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 35561817)

  • 21. Diagnostic biomarkers for Parkinson's disease: focus on α-synuclein in cerebrospinal fluid.
    Kalia LV
    Parkinsonism Relat Disord; 2019 Feb; 59():21-25. PubMed ID: 30466800
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tau/α-synuclein ratio and inflammatory proteins in Parkinson's disease: An exploratory study.
    Delgado-Alvarado M; Gago B; Gorostidi A; Jiménez-Urbieta H; Dacosta-Aguayo R; Navalpotro-Gómez I; Ruiz-Martínez J; Bergareche A; Martí-Massó JF; Martínez-Lage P; Izagirre A; Rodríguez-Oroz MC
    Mov Disord; 2017 Jul; 32(7):1066-1073. PubMed ID: 28548309
    [TBL] [Abstract][Full Text] [Related]  

  • 23. α-Synuclein and DJ-1 as potential biological fluid biomarkers for Parkinson's Disease.
    Waragai M; Sekiyama K; Sekigawa A; Takamatsu Y; Fujita M; Hashimoto M
    Int J Mol Sci; 2010 Oct; 11(11):4257-66. PubMed ID: 21151436
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reduced α-synuclein levels in cerebrospinal fluid in Parkinson's disease are unrelated to clinical and imaging measures of disease severity.
    van Dijk KD; Bidinosti M; Weiss A; Raijmakers P; Berendse HW; van de Berg WD
    Eur J Neurol; 2014 Mar; 21(3):388-94. PubMed ID: 23631635
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Plasma and serum alpha-synuclein as a biomarker in Parkinson's disease: A meta-analysis.
    Zubelzu M; Morera-Herreras T; Irastorza G; Gómez-Esteban JC; Murueta-Goyena A
    Parkinsonism Relat Disord; 2022 Jun; 99():107-115. PubMed ID: 35717321
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Longitudinal changes in CSF alpha-synuclein species reflect Parkinson's disease progression.
    Majbour NK; Vaikath NN; Eusebi P; Chiasserini D; Ardah M; Varghese S; Haque ME; Tokuda T; Auinger P; Calabresi P; Parnetti L; El-Agnaf OM
    Mov Disord; 2016 Oct; 31(10):1535-1542. PubMed ID: 27548849
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enzyme-linked immunosorbent assays for α-synuclein with species and multimeric state specificities.
    Lee HJ; Bae EJ; Jang A; Ho DH; Cho ED; Suk JE; Yun YM; Lee SJ
    J Neurosci Methods; 2011 Aug; 199(2):249-57. PubMed ID: 21658411
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Validation of a quantitative cerebrospinal fluid alpha-synuclein assay in a European-wide interlaboratory study.
    Kruse N; Persson S; Alcolea D; Bahl JM; Baldeiras I; Capello E; Chiasserini D; Bocchio Chiavetto L; Emersic A; Engelborghs S; Eren E; Fladby T; Frisoni G; García-Ayllón MS; Genc S; Gkatzima O; Heegaard NH; Janeiro AM; Kováčech B; Kuiperij HB; Leitão MJ; Lleó A; Martins M; Matos M; Mollergard HM; Nobili F; Öhrfelt A; Parnetti L; de Oliveira CR; Rot U; Sáez-Valero J; Struyfs H; Tanassi JT; Taylor P; Tsolaki M; Vanmechelen E; Verbeek MM; Zilka N; Blennow K; Zetterberg H; Mollenhauer B
    Neurobiol Aging; 2015 Sep; 36(9):2587-96. PubMed ID: 26093515
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evolution of cerebrospinal fluid total α-synuclein in Parkinson's disease.
    Førland MG; Öhrfelt A; Dalen I; Tysnes OB; Blennow K; Zetterberg H; Pedersen KF; Alves G; Lange J
    Parkinsonism Relat Disord; 2018 Apr; 49():4-8. PubMed ID: 29409704
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diagnostic utility of cerebrospinal fluid α-synuclein in Parkinson's disease: A systematic review and meta-analysis.
    Eusebi P; Giannandrea D; Biscetti L; Abraha I; Chiasserini D; Orso M; Calabresi P; Parnetti L
    Mov Disord; 2017 Oct; 32(10):1389-1400. PubMed ID: 28880418
    [TBL] [Abstract][Full Text] [Related]  

  • 31. α-Synuclein species as potential cerebrospinal fluid biomarkers for dementia with lewy bodies.
    van Steenoven I; Majbour NK; Vaikath NN; Berendse HW; van der Flier WM; van de Berg WDJ; Teunissen CE; Lemstra AW; El-Agnaf OMA
    Mov Disord; 2018 Nov; 33(11):1724-1733. PubMed ID: 30440090
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CSF α-synuclein and UCH-L1 levels in Parkinson's disease and atypical parkinsonian disorders.
    Mondello S; Constantinescu R; Zetterberg H; Andreasson U; Holmberg B; Jeromin A
    Parkinsonism Relat Disord; 2014 Apr; 20(4):382-7. PubMed ID: 24507721
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cerebrospinal fluid, plasma, and saliva in the BioFIND study: Relationships among biomarkers and Parkinson's disease Features.
    Goldman JG; Andrews H; Amara A; Naito A; Alcalay RN; Shaw LM; Taylor P; Xie T; Tuite P; Henchcliffe C; Hogarth P; Frank S; Saint-Hilaire MH; Frasier M; Arnedo V; Reimer AN; Sutherland M; Swanson-Fischer C; Gwinn K; ; Kang UJ
    Mov Disord; 2018 Feb; 33(2):282-288. PubMed ID: 29205509
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CSF or serum neurofilament light added to α-Synuclein panel discriminates Parkinson's from controls.
    Oosterveld LP; Verberk IMW; Majbour NK; El-Agnaf OM; Weinstein HC; Berendse HW; Teunissen CE; van de Berg WDJ
    Mov Disord; 2020 Feb; 35(2):288-295. PubMed ID: 31737952
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cerebrospinal fluid lysosomal enzymes and alpha-synuclein in Parkinson's disease.
    Parnetti L; Chiasserini D; Persichetti E; Eusebi P; Varghese S; Qureshi MM; Dardis A; Deganuto M; De Carlo C; Castrioto A; Balducci C; Paciotti S; Tambasco N; Bembi B; Bonanni L; Onofrj M; Rossi A; Beccari T; El-Agnaf O; Calabresi P
    Mov Disord; 2014 Jul; 29(8):1019-27. PubMed ID: 24436092
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A more efficient enzyme-linked immunosorbent assay for measurement of alpha-synuclein in cerebrospinal fluid.
    van Geel WJ; Abdo WF; Melis R; Williams S; Bloem BR; Verbeek MM
    J Neurosci Methods; 2008 Feb; 168(1):182-5. PubMed ID: 17976734
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of Different Platform Immunoassays for the Measurement of Plasma Alpha-Synuclein in Parkinson's Disease Patients.
    Youssef P; Kim WS; Halliday GM; Lewis SJG; Dzamko N
    J Parkinsons Dis; 2021; 11(4):1761-1772. PubMed ID: 34151860
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development of electrochemiluminescence-based singleplex and multiplex assays for the quantification of α-synuclein and other proteins in cerebrospinal fluid.
    Kruse N; Schulz-Schaeffer WJ; Schlossmacher MG; Mollenhauer B
    Methods; 2012 Apr; 56(4):514-8. PubMed ID: 22465793
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Autoimmune antibody decline in Parkinson's disease and Multiple System Atrophy; a step towards immunotherapeutic strategies.
    Brudek T; Winge K; Folke J; Christensen S; Fog K; Pakkenberg B; Pedersen LØ
    Mol Neurodegener; 2017 Jun; 12(1):44. PubMed ID: 28592329
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Total CSF α-synuclein is lower in de novo Parkinson patients than in healthy subjects.
    Mollenhauer B; Trautmann E; Taylor P; Manninger P; Sixel-Döring F; Ebentheuer J; Trenkwalder C; Schlossmacher MG
    Neurosci Lett; 2013 Jan; 532():44-8. PubMed ID: 23149132
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.